Catalog No.
Product Name
Application
Product Information
Citations
- Allopurinol is a purine analog; it is a structural isomer of hypoxanthine (a naturally occurring purine in the body) and is an inhibitor of the enzyme xanthine oxidase.
-
Lipoxygenase Inhibitor
Baicalein is a flavonoid originally isolated from the roots of Scutellaria baicalensis Georgi. Baicalein inhibits lipid peroxidation, as assessed by production of TBARS, with an IC50 value of 5 µM.
- Wafa Naji Shnaikat, .et al. , Iraqi J Pharm Sci, 2023, 31(Suppl.):92-99
-
xanthine oxidase inhibitor
Febuxostat is a non-purine inhibitor of xanthine oxidase (Ki = 1.2 nM). -
Xanthine oxidase inhibitor
Oxipurinol (Oxipurinol), the major active metabolite of Allopurinol, is an inhibitor of xanthine oxidase. Oxipurinol can be used to regulate blood urate levels and treat gout. -
XOR Inhibitor
Topiroxostat (FYX-051) is a novel and potent xanthine oxidoreductase (XOR) inhibitor with IC50 value of 5.3 nM. - Phytic Acid is a constituent of wheat bran shown to have antineoplastic action in colon carcinogenesis.
-
CYP2C9 inhibitor
Benzbromarone is a CYP2C9 inhibitor, it binds to CYP2C9 with Ki value of 19.3 nM. -
xanthine oxidase inhibitor
Febuxostat D9 is deuterium labeled Febuxostat, which is a selective xanthine oxidase inhibitor with Ki of 0.6 nM. - H-Tyr-Phe-OH (L-Tyrosyl-L-phenylalanine) is an orally active inhibitor of Angiotensin converting enzyme (ACE), with an inhibiton rate of 48% at 50 μM. H-Tyr-Phe-OH can be used as an biomarker for differentiating benign thyroid nodules (BTN) from thyroid cancer (TC). H-Tyr-Phe-OH exhibits xanthine oxidase inhibition (uric acid lowering) activity and serves as regulator in IL-8 production in neutrophil-like cells.
-
XO Inhibitor
Procyanidin B2 3′-O-gallate is a potent inhibitor of xanthine oxidase (XO), exhibiting an IC50 of 24.24 μM and a Ki value of 6.16 μM. Its notable antioxidant activity allows for the reduction of UV-induced α-tocopheroxyl formation. This compound is suitable for research related to hyperuricemia and gout, providing a valuable tool for investigating therapeutic strategies in these conditions. -
DAAO Inhibitor
Luvadaxistat is a highly selective and potent inhibitor of D-amino acid oxidase (DAAO), demonstrating an IC50 value of 14 nM in the inhibition of oxidative deamination of D-serine. This compound significantly elevates D-serine concentrations in various biological matrices, including the rodent brain, plasma, and cerebrospinal fluid. Luvadaxistat holds promise as a valuable tool for research into schizophrenia and related neurobiological disorders. -
HDX Inhibitor
2-Methylacetophenone is a potent xanthine dehydrogenase (XDH) inhibitor that competently interacts with the XDH active site, effectively preventing the conversion of xanthine to uric acid. This compound is instrumental in research applications focused on hyperuricemia and conditions related to elevated uric acid levels. Its use can deepen the understanding of purine metabolism and contribute to the development of therapeutic strategies. -
Xanthine Oxidase Inhibitor
Tigulixostat is a selective xanthine oxidase inhibitor with potent activity, demonstrating IC50 values of 0.003 µM in bovine milk and 0.073 µM in rat plasma. This compound effectively lowers serum uric acid levels and is utilized in research focusing on gout and hyperuricemia. Its oral bioavailability and targeted mechanism make it a valuable tool in studying these conditions. -
Urate Oxidase
Rasburicase is a recombinant urate oxidase that catalyzes the oxidation of uric acid to allantoin, a more soluble compound. This mechanism effectively lowers blood uric acid levels, alleviates inflammation, and mitigates kidney damage associated with uric acid crystallization. Rasburicase is utilized in research related to severe hyperuricemia, particularly in conditions such as tumor lysis syndrome (TLS) and refractory gout. Its capacity to reduce uric acid levels makes it a valuable tool in studying the pathophysiology of related disorders. -
XOD Inhibitor
7,8,3′,4′-Tetrahydroxyflavone is a potent inhibitor of xanthine oxidase (XOD) with an IC50 value of 10.488 µM. This compound demonstrates significant inhibitory activity, making it a valuable tool for studies related to oxidative stress and purine metabolism. Research applications include investigating its potential therapeutic effects in conditions associated with hyperuricemia and gout. -
Xanthine Oxidase Inhibitor
8-Azaadenine is a potent inhibitor of xanthine oxidase, exhibiting an IC50 value of 0.54 μM and a Ki of 0.66 μM. This compound can be synthesized through the metabolism of 8-Azaadenosine and is capable of integrating into polynucleotide chains alongside 8-Azaguanine, thereby influencing purine metabolism. 8-Azaadenine serves as a valuable tool in cancer research, enabling investigations into therapeutic strategies targeting purine biosynthesis pathways. -
DAO Inhibitor
DAO-IN-1 is a potent inhibitor of D-amino acid oxidase (DAO), exhibiting an IC50 value of 269 nM. By inhibiting DAO, it effectively modulates D-serine levels, a crucial co-agonist of NMDA receptors. This compound is valuable for research investigating the roles of D-serine and NMDA receptor modulation in various neurological disorders. -
XO Inhibitor
Myricetin 3-O-galactoside is a potent xanthine oxidase (XO) inhibitor known for its antioxidant properties. It effectively reduces lipid peroxidation, exhibiting an IC50 value of 160 μg/mL. This compound is valuable for research applications focused on oxidative stress and related pathologies, providing insight into therapeutic approaches targeting reactive oxygen species. -
Xanthine Oxidase Inhibitor
O-Desisobutyl-O-n-propyl Febuxostat is an xanthine oxidase inhibitor that plays a crucial role in the modulation of uric acid levels. Its primary mechanism involves the inhibition of xanthine oxidase activity, which can be beneficial in the treatment of gout and hyperuricemia. This compound is valuable for research applications focused on purine metabolism, oxidative stress, and related metabolic disorders. Scientists can utilize it to explore therapeutic strategies targeting inflammatory pathways associated with elevated uric acid. -
XOR Inhibitor
Niraxostat is an orally active xanthine oxidoreductase (XOR) inhibitor. It is utilized in research focused on hyperuricemia and related pathologies where XOR plays a significant role in disease mechanisms. By inhibiting XOR, Niraxostat can help elucidate the biochemical pathways involved in uric acid metabolism and its associated conditions. -
Xanthine Oxidase Inhibitor
Azacosterol, a potent xanthine oxidase inhibitor, is known for its role as a DHCR24 inhibitor. This compound facilitates a series of biochemical reactions in cortical neurons, contributing to its significance in neurological research. Its unique mechanism positions it as a valuable tool in studies investigating oxidative stress and related pathways in various biological contexts. -
XO Inhibitor
Febuxostat sodium is a selective non-purine xanthine oxidase (XO) inhibitor, exhibiting a potent Ki value of 0.6 nM. It is primarily utilized in the investigation of hyperuricemia and gout due to its ability to effectively lower urate levels. This compound serves as a valuable tool for studying the biochemical pathways associated with purine metabolism and the therapeutic effects in gout-related conditions. -
XO Inhibitor
Xanthine oxidase-IN-7 is a potent xanthine oxidase (XO) inhibitor with an IC50 of 0.36 µM. It effectively lowers serum uric acid levels, making it a valuable tool for studying hyperuricemia and gout. This compound has significant potential in research applications focused on disorders related to uric acid metabolism. -
Xanthine Oxidoreductase Inhibitor
Xanthine oxidoreductase-IN-5 is a potent inhibitor of xanthine oxidoreductase (XOR), exhibiting an IC50 of 55 nM. This compound is employed in research focused on acute hyperuricemia, facilitating the investigation of uric acid metabolism and its associated disorders. Xanthine oxidoreductase-IN-5 serves as a valuable tool for exploring therapeutic strategies aimed at managing conditions related to elevated uric acid levels. -
XOR Inhibitor
Xanthine oxidoreductase-IN-2 is a potent inhibitor of xanthine oxidoreductase (XOR) with an IC50 value of 7.2 nM. This compound exhibits significant hypouricemic effects in murine models, making it a valuable tool for research into disorders related to uric acid metabolism. It is suitable for investigating the role of XOR in conditions such as gout and oxidative stress-related diseases. -
Anti-hyperuricemic Agent
NARS-3′ is a selective reversible inhibitor of xanthine oxidase, exhibiting an IC50 of 21.01 μM. This compound effectively competes with substrates to diminish uric acid production, demonstrating potential in mitigating renal damage in hyperuricemia models. NARS-3′ is suitable for research applications focused on hyperuricemia and related metabolic disorders. -
Antioxidant Agent
Antioxidant agent-13 is a potent antioxidant compound that targets DPPH and FRAP, exhibiting inhibitory activity with IC50 values of 80.33 μM and 85.69 μM, respectively. Additionally, this compound effectively inhibits lipoxygenase (LOX) and xanthine oxidase (XO) with IC50 values of 16.85 μM and 23.01 μM, respectively. Antioxidant agent-13 is valuable for research focused on oxidative stress and related pathological conditions, providing insights into potential therapeutic applications. -
Xanthine Oxidase Inhibitor
Xanthine oxidase-IN-19 is a potent inhibitor of xanthine oxidase (XO) with an IC50 of 0.2 μM. This compound effectively reduces serum uric acid levels in models of acute hyperuricemia, making it valuable for research into hyperuricemia-related conditions. Xanthine oxidase-IN-19 serves as a useful tool for studying the biochemical and physiological impacts of XO inhibition. -
Xanthine Oxidase Inhibitor
Xanthine oxidase-IN-20 is a highly potent inhibitor of xanthine oxidase, exhibiting an IC50 of 1.7 nM. This compound demonstrates significant efficacy in reducing serum uric acid levels in acute hyperuricemia models in both mice and rats. With a favorable safety profile, Xanthine oxidase-IN-20 is suitable for research focusing on hyperuricemia and gout. -
Xanthine Oxidase Inhibitor
Ilexoside O is a triterpene saponin that functions as a xanthine oxidase inhibitor. Isolated from the roots of Ilex pubescens, it demonstrates moderate inhibitory activity against xanthine oxidase with an IC50 value of 53.05 μM. This compound is relevant for studies investigating oxidative stress and related metabolic pathways. Its application may extend to research on conditions such as gout and hyperuricemia. -
Uricosuric Agent
Smilaxchinoside A is a steroidal glycoside that acts as a potent uricosuric agent. It effectively reduces serum uric acid levels by inhibiting xanthine oxidase (XOD) and downregulating renal urate transporter 1 (mURAT1) expression. This compound is valuable in the study of hyperuricemia and related disorders. -
Xanthine Oxidase Inhibitor
Tricetin 3',4',5'-trimethyl ether, a selective xanthine oxidase inhibitor, exhibits competitive inhibition with an IC50 value of 0.51 μM and a Ki of 0.37 μM. Derived from the flowers of Chrysanthemum sinensea, this flavone glucoside demonstrates significant biological activity relevant to oxidative stress and inflammation research. It is a valuable tool for studies exploring the modulation of purine metabolism and the potential therapeutic implications in conditions associated with elevated xanthine oxidase activity. -
Xanthine Oxidase Inhibitor
Fraxamoside is a competitive inhibitor of xanthine oxidase, demonstrating an IC50 value of 16.1 μM and a Ki of 0.9 μM. This compound effectively modulates the activity of xanthine oxidase, an enzyme involved in purine metabolism and reactive oxygen species production. Fraxamoside is primarily utilized in research focused on conditions associated with elevated uric acid levels, oxidative stress, and inflammation. -
Xanthine Oxidase Inhibitor
Aurantiamide benzoate acts as a potent inhibitor of xanthine oxidase, exhibiting an IC50 value of 70 μM. This natural product is derived from the tropical medicinal plants Cunila spicata and Hyptis fasciculata. Its inhibition of xanthine oxidase suggests potential applications in the treatment of conditions associated with elevated uric acid levels, such as gout and certain cardiovascular diseases. -
Xanthine Oxidoreductase Inhibitor
Xanthine oxidoreductase-IN-3 is a potent inhibitor of xanthine oxidoreductase (XOR), characterized by an IC50 of 26.3 nM. This compound is primarily utilized in research focused on acute hyperuricemia, demonstrating its potential to modulate uric acid levels effectively. Its oral bioavailability makes it a valuable tool in exploring therapeutic approaches for conditions associated with elevated uric acid. -
XO Inhibitor
Xanthine oxidase-IN-5 is a potent and orally active inhibitor of xanthine oxidase (XO), exhibiting an IC50 value of 0.70 μM. This compound demonstrates favorable ligand efficiency (LE) and lipophilic ligand efficiency (LLE) values of 0.33 and 3.41, respectively. Xanthine oxidase-IN-5 has shown significant hypouricemic effects in hyperuricemic rat models, making it a valuable tool for research into conditions related to elevated uric acid levels. -
Xanthine Oxidase Inhibitor
Forsythoside F is a potent inhibitor of xanthine oxidase, an enzyme implicated in the production of uric acid. It exhibits antihyperuricemic properties, making it relevant for research focused on conditions such as gout and other disorders associated with elevated uric acid levels. This compound is valuable for studies investigating the modulation of uric acid metabolism and related physiological pathways. -
XOD Inhibitor
Xanthine oxidase-IN-17 is a selective inhibitor of xanthine oxidase (XOD), demonstrating an IC50 of 298 nM and a Ki of 167 nM. By inhibiting XOD, it effectively reduces the generation of superoxide radicals and decreases uric acid production. This compound exhibits no cytotoxic effects on AML-12 hepatocyte cells and is valuable for research addressing hyperuricemia and gout. -
Xanthine Oxidase Inhibitor
Eupatoriochromene is a chromene compound that serves as an inhibitor of xanthine oxidase (XO). By inhibiting XO activity, it has potential implications in the management of conditions associated with elevated uric acid levels, such as gout. This compound can be utilized in research applications focused on purine metabolism and oxidative stress. -
Baicalein Metabolite
Baicalein 6-O-glucoside is a glucuronidated metabolite of Baicalein, primarily targeting various biological pathways via its antioxidant properties. This compound exhibits significant anti-inflammatory and neuroprotective activities, making it valuable for research in pharmacology and toxicology. Its potential applications include studying metabolic pathways and evaluating therapeutic effects in conditions such as neurodegenerative diseases and oxidative stress-related disorders. -
Xanthine Oxidase
Xanthine oxidoreductase-IN-1 specifically targets xanthine oxidase, exhibiting a high inhibitory potency with an IC50 value of 7.0 nM. This compound serves as a valuable tool in biochemical research to investigate the role of xanthine oxidase in various physiological and pathological processes. Its application is paramount in studies related to oxidative stress, inflammation, and purine metabolism. -
XOD Inhibitor
Xanthine oxidase-IN-8 (Icarisids J) is a selective inhibitor of xanthine oxidase (XOD) with an IC50 value of 29.71 μM. This compound demonstrates significant activity in reducing uric acid production, making it useful for studying conditions associated with hyperuricemia, such as gout. Its inhibitory effects on XOD can assist in elucidating the enzyme's role in various metabolic pathways and potential therapeutic interventions. -
Xanthine Oxidase Inhibitor
Angexostat is a potent xanthine oxidase inhibitor, effectively blocking its enzymatic activity. With demonstrated high permeability, Angexostat inhibits CYP2C9 with an IC50 of 18.1 μM. This compound is valuable in research focused on xanthine oxidase-related conditions, including hyperuricemia and gout, providing insights into potential therapeutic strategies. -
XOR Inhibitor
Xanthine oxidoreductase-IN-4 is a potent inhibitor of xanthine oxidoreductase (XOR) with an IC50 value of 29.3 nM. This compound demonstrates significant inhibitory activity, making it a valuable tool for investigating metabolic disorders associated with hyperuricemia. Xanthine oxidoreductase-IN-4 can facilitate research aimed at understanding the role of XOR in uric acid metabolism and related conditions. -
Xanthine Oxidase Inhibitor
Xanthine oxidase-IN-10 is a potent inhibitor of xanthine oxidase, an enzyme involved in the production of reactive oxygen species. By inhibiting this enzyme, Xanthine oxidase-IN-10 demonstrates potential anti-inflammatory and antioxidant properties. This reagent is valuable for research applications in understanding gout, hyperuricemia, and oxidative stress-related conditions. -
Xanthine Oxidase Inhibitor
(+/-)-Epicatechin is a xanthine oxidase inhibitor with an IC50 value of 982.14 μM. This compound, found in Semen Plantaginis (Plantago seed), showcases potential in research related to hyperuricemia and gout. Its ability to modulate xanthine oxidase activity makes it a valuable tool for investigating mechanisms underlying uric acid metabolism and associated pathologies. -
XO Inhibitor
Tetrahydroamentoflavone is a potent xanthine oxidase (XO) inhibitor, demonstrating significant inhibitory activity with IC50 and Ki values of 92 nM and 0.982 μM, respectively. This compound has potential applications in the study of inflammatory disorders and gout, making it a valuable tool for researchers investigating these conditions. Its ability to modulate XO activity positions it as a promising candidate for further exploration in therapeutic contexts. -
XOD Inhibitor
Xanthine oxidase-IN-9 is a selective inhibitor of xanthine oxidase (XOD), exhibiting an IC50 value of 31.81 μM. This compound is instrumental in studying disorders associated with increased XOD activity, including gout and oxidative stress-related conditions. Its biological activity makes it a valuable tool in biochemical research aimed at developing therapeutic strategies targeting purine metabolism and reactive oxygen species. -
Xanthine Oxidase Inhibitor
Prudomestin is a potent xanthine oxidase inhibitor derived from the heartwood of Prunus domestica. With an IC50 of approximately 6 µM, it exhibits significant inhibitory activity against XO, a key enzyme involved in purine metabolism and the production of reactive oxygen species. This compound is valuable for research applications focused on oxidative stress, gout, and related inflammatory conditions.
